The Association for Clinical Oncology (ASCO) today released a statement applauding the implementation of the Research to Accelerate Cures and Equity (RACE) for Children Act. As of today, applications to the Food and Drug Administration for marketing approval of new drugs and biological products—including orphan drugs that have relevance to pediatric cancer—must include an assessment of pediatric use.
August 18, 2020
August 14, 2020
Greater Coverage, Patient Education, and Research for Telemedicine Needed During Pandemic and Beyond
The American Society of Clinical Oncology released today a position statement that recommends specific actions for applying telemedicine in cancer care during the pandenic and after its expiration.
August 12, 2020
One of the nation’s leading cancer organizations today called for new actions to reduce disparities in cancer outcomes affecting racial and ethnic minorities, rural populations, sexual and gender minorities, people without insurance, and other disadvantaged populations.
July 30, 2020
The American Society of Clinical Oncology (ASCO) released a position statement that raises concerns about home infusion of anticancer therapy and Centers for Medicare & Medicaid Services (CMS) regulations regarding the practice.
July 27, 2020
Jonathan W. Friedberg, MD, MMSc, has been appointed as the next editor-in-chief of the Journal of Clinical Oncology (JCO), the flagship journal of the American Society of Clinical Oncology (ASCO).
July 20, 2020
ASCO and ACCC today announced a new collaboration to foster participation in cancer treatment trials to more fully reflect the diversity of people at risk for or living with cancer.
July 17, 2020
Eighteen Oncology Practices Receive Quality Certification from the Association for Clinical Oncology
The Association of Clinical Oncology congratulates the eighteen practices that prioritized the quality of care they provide by achieving the Quality Oncology Practice Initiative (QOPI®) Certification in the second quarter of 2020.
June 25, 2020
Nancy R. Daly, MS, MPH, has been named Chief Executive Officer of Conquer Cancer, the American Society of Clinical Oncology (ASCO) Foundation, a move that reflects Ms. Daly’s growing leadership of the organization and successful expansion of its research grants and awards program.
June 10, 2020
On June 10, ASCO’s CancerLinQ® launched the SmartLinQ™ QOPI® Certification Pathway, an application that empowers oncology practices to automate quality measure tracking and reporting for participation in ASCO’s Quality Oncology Practice Initiative (QOPI) Certification Program, a three-year certification recognizing practices’ commitment to high-quality care for outpatient oncology practices.
June 4, 2020
On June 4 the American Society of Clinical Oncology announced record-breaking attendance at its three-day virtual scientific meeting, held online from Friday, May 29, through Sunday, May 31. More than 42,700 attendees from 138 countries have participated thus far, learning virtually about new clinical cancer advances in every area of cancer research.
May 29, 2020
New CancerLinQ Discovery® Research Platform Offers Researchers Easy Access to Real-World Cancer Data
On May 29, ASCO’s CancerLinQ® announced that it launched a new platform for CancerLinQ Discovery®, its de-identified real-world cancer data product for researchers across the cancer community.
May 29, 2020
Positive results from two cohorts of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study provide real world evidence to support recent clinical trial data that demonstrate a role for olaparib (Lynparza) in the treatment of advanced prostate and pancreatic cancers with BRCA1/2 inactivating mutations.
May 28, 2020
Conquer Cancer, the ASCO Foundation, is honored to announce the recipients of its awards supporting researchers with projects spanning many areas in cancer care, including immunotherapy, lung, breast cancer, and palliative care.
May 28, 2020
ALEXANDRIA, Va. — In a small, phase II study of a very rare cancer that develops inside a woman’s uterus during or after pregnancy, treatment with avelumab (Bavencio) potentially cured 8 out of 15 women with cancer that was resistant to single-agent chemotherapy. This is the first trial exploring use of immunotherapy in patients with gestational trophoblastic tumors (GTT) and suggests that avelumab may be a new therapeutic option for these patients. The results will be presented during the virtual scientific program of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting.
May 28, 2020
Treatment with avelumab combined with best supportive care following chemotherapy significantly extended overall survival compared with best supportive care alone in patients with advanced urothelial cancer in the JAVELIN Bladder 100 trial.
Pages |